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Background: The anti-Müllerian hormone (AMH) is a dimeric protein secreted by the female 
ovaries and has two fundamental roles in follicle genesis. It delays the entrance of the primordial 
follicle into the pool of follicles in growth and diminishes the sensitivity of the ovarian follicle 
towards follicle-stimulating hormone (FSH). The purpose of this work was to study the AMH 
(nv 2.0–6.8 ng/mL) as a marker during assisted reproductive technology (ART), in order to 
identify cases of infertility due to polycystic ovarian syndrome (PCOS). This syndrome affects 
10% of women with infertility problems, and a new biological marker could be useful to gen-
eral practitioners of internal medicine to help generate the suspicion of PCOS so that they can 
refer the patient to the gynecologist for confirmation.
Methods: This study enrolled 236 patients aged 26–46 years undergoing assisted reproductive 
technology at the Institute for Maternal and Child Health, Trieste, Italy. On the third day of the 
ovarian cycle, the patients were given doses of AMH, FSH, and luteinizing hormone (LH, in 
cases of AMH . 2.0–6.8 ng/mL). A control pelvic ultrasound was also carried out.
Results: We identified 57 patients who were starting in vitro fertilization or embryo transfer 
with AMH values within the normal range (3.64 ± 1.51 ng/mL), 77 with values below normal 
(1.38 ± 0.32 ng/mL), and 96 cases with undetectable values of AMH. Six patients had very 
high AMH levels (10.0 ± 2.28 ng/mL) and, of these, five were found to have PCOS on pelvic 
ultrasound examination (P , 0.05). We also found inverse correlations between AMH levels 
and age (r = −0.52) and between AMH and FSH levels (r = −0.32).
Conclusion: In clinical practice it is common to encounter patients who turn to medicine in 
search of a cure for female infertility. In our experience, AMH two or three times the normal 
amount (10 ± 2.28 ng/mL), is a good indication of PCOS and infertility.
Keywords: anti-Müllerian hormone, serum level, follicle development, polycystic ovarian 
syndrome, predictive marker
Introduction
Anti-Müllerian hormone (AMH), also known as Müller inhibiting factor or   Müller 
inhibiting substance, is a glycoprotein formed from two identical subunits, each 
with a molecular weight of 72 kDa. The hormone is part of the growth factor   family, 
which includes 35 different peptide structures, including inhibin, activin, growth 
differentiation factor, and bone morphogenic protein.1 Up until a few years ago, AMH 
was known mainly for its role in the differentiation of male sexual characteristics.2,3
AMH is not secreted in the female embryo, allowing development of the female 
sexual organs, starting from the Müller ducts which do not regress, although they differ 
in the uterus, fallopian tube, and upper part of the vagina. Expression of the hormone 
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in women is different at various stages of life, and starts to 
be detected at week 36 of gestation. Its concentration reaches 
a maximum during puberty, begins to decrease in adulthood, 
and disappears completely following the menopause. AMH, 
produced from the granulosa cells of the primary follicles, 
reaches maximum expression in the preantral follicles, with 
lesser secretion by the greater antral follicles. At this point, 
growth starts to become dependent on follicle-stimulating 
hormone (FSH). The data suggest that AMH is a factor in 
regulation during the initial recruitment and cyclical recruit-
ment phases leading to selection of the dominant follicle, and 
that it has a potential autocrine and paracrine role in follicular 
development in the female ovaries.
After a period of optimal fertility at age 18–30 years, 
oocyte quality diminishes in parallel with a progressive loss 
of follicles. In women with normal ovulation, serum levels 
of AMH slowly increase, reaching a peak during puberty 
and then progressively diminishing with the passage of 
time. Their lessening is detected by markers of ovarian age. 
Moreover, recent studies have shown that AMH is correlated 
with the number of small antral follicles. This observation 
supports the hypothesis that serum levels of AMH can reflect 
the state of the ovarian follicles better (given its relative sta-
bility during the entire cycle) than the more usual hormonal 
markers (FSH, luteinizing hormone [LH], estradiol, and 
inhibin B), and demonstrates how AMH can be a favorable 
candidate as a marker of the ovarian reservoir.4–6
Infertility and polycystic  
ovary syndrome. Meaning  
of anti-Müllerian hormone
Reproductive behavior has changed dramatically in the last 
century, and it is important to be able to identify loss of 
fertility in a woman as early as possible. More and more 
women are now delaying pregnancy to a more advanced age, 
when the quality and amount of ovarian follicles begins to 
decrease. The first sign of aging is increased levels of FSH 
at the age of 35–40 years, when the menstrual periods tend 
to shorten. Therefore, determining ovarian age is important 
for patients in whom treatment with in vitro fertilization is 
proposed, keeping in mind that the probability of pregnancy 
and subsequent birth of a child gradually diminishes from 
the age of 37–38 years onwards.
From this point of view, AMH has been identified and 
proposed for evaluation of responses in patients undergoing 
assisted reproductive technology. It is now a potential 
  candidate for inclusion in the clinical report, in order to be 
able to construct a strategy which is targeted and personalized 
to the characteristics of the patient, and able to increase the 
benefits of treatment from the physiological, psychological, 
and economic points of view.7–9
Numerous studies have advocated the use of AMH in 
assisted reproductive technology as a noninvasive test in 
order to estimate the antral follicle count.10,11
AMH is now proposed as a hormonal test in the study 
of feminine infertility and in the diagnosis of PCOS. The 
diagnosis depends on two of the following criteria: clinical 
and/or biochemical evidence of hyperandrogenism (with 
exclusion of other causes of excess androgen), oligo or 
anovulation, and polycystic ovaries (European Society of 
Human Reproduction and American Society for Reproductive 
Medicine, Consensus Conference, Rotterdam, 2003).12,13 Such 
data lead us to conclude that inclusion of serum AMH levels 
in routine tests for patients undergoing assisted reproductive 
technology is useful, both quantitatively and qualitatively, 
not only in the study of patient responses to clinical treatment 
for infertility, but also in clinical assessment.14–20
Use of anti-Müllerian hormone
Numerous tests and markers are used in order to identify 
pathologies involving the ovaries. Amongst these are 
exclusion serum markers of other endocrinopathies (prolactin, 
thyroid stimulating hormone, 17-hydroxyprogesterone), 
confirmation of serum markers of ovarian pathology 
(FSH, LH, estradiol, inhibin B), invasive scan markers 
(transvaginal or laparoscopic ultrasound for antral follicle 
count) and, over the last few years, AMH levels. There 
are also other confirmation and monitoring serum tests for 
PCOS (androstenedione, testosterone, free testosterone, 
dehydroepiandrosterone). This diagnosis will not only 
render possible a targeted and personalized therapy in order 
to achieve a greater probability of a positive outcome of 
treatment, but will also avoid potential harmful effects 
of treatment, that could eventually preclude assisted 
reproduction altogether.
Aim
In this study, we evaluated the value of serum analysis of 
AMH as a diagnostic test in patients undergoing assisted 
fertility, in order to diagnose PCOS prior to treatment. 
The purpose was to identify a cost-effective, noninvasive 
clinical method for assessing ovarian pathology, which 
would also reduce psychological stress for the patient. AMH 
can be measured on any day of the cycle, because there are 
no fluctuations and it has low cyclical interindividual or 
intraindividual variability.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Materials and methods
The study was carried out on 236 serum samples taken from 
women aged 26–46 years and scheduled for exogenous 
gonadotrophin treatment for infertility at the Institute for 
Maternal and Child Health, Burlo Garofolo, Trieste, between 
September 2010 and June 2011. All patients signed an 
informed consent form before entering the study, which was 
approved by the ethics committee at our institution.
The serum samples were centrifuged to separate the 
  cellular component. The sample centrifugation for 5’, as 
described in the manufacturer’s instructions, was done to 
remove residual fibrin and cellular matter, prior to stor-
age. Lipemic or hemolyzed samples have been eliminated. 
The serum was stored at 2°C–8°C for up to 24 hours 
and was then frozen at −20°C. The confidence limits for 
AMH controls were printed on the control vial labels and 
intra- and inter-test precision was within two standard 
deviations (±2 SD).
Measurement of AMH levels was carried out on the 
third day of the ovarian cycle using an enzyme-linked 
immunosorbent assay (Beckman Coulter, Immunotech, 
DSL Diagnostic System Laboratories, Marseille, France). 
This quantitative, specific, and sensitive technique allows 
measurement of small amounts of molecules present in 
  biological samples. Moreover, it is possible to analyze a high 
number of samples in a short space of time, as a result of 
being able to use microplates. It is based on a colorimetric 
system, with the intensity of color being directly proportional 
to the concentration of the antigen, which is measured by 
spectrophotometry.
The field of measurement comprises concentration of 
the analyte sensitivity to the concentration of the highest 
calibrator standard, from 0.14 ng/mL to 21 ng/mL. The 
  precision is given by an intratest and an intertest, with 
  respective variation coefficients of 12.3% and 14.2%, 
  respectively. The instrument used for analysis in the enzyme-
linked immunosorbent assay was a semiautomatic spectro-
photometer (Pantech, New York, NY). The enzyme-linked 
immunosorbent assay used was a typical sandwich test, the 
peculiarity of which concerns a second biotinylated mono-
clonal antibody directed against the antigen and conjugated 
with the enzyme streptavidin and horseradish peroxidase. 
Streptavidin is a purified tetrameric protein of bacterial origin 
(Streptomyces avidinii). In order to estimate the AMH con-
centration in the study samples, a calibration curve for inter-
polation was constructed, using standard AMH samples with 
Table 1 Suggested definitions according to AMH values for the hormone therapy by ART (IRCCS Burlo Garofolo)
AMH nv  
2.0–6.8 ng/mL
Normal responders  
meana
Poor responders  
meanb
No responders 
meanc
POCS 
meand
Values ng/mL 3.64 1.38 0.4 10.0
Years 35 36.9 37.5 31
Patient number 57 77 96 6
Pelvic ultrasound normal normal normal Pathological
Notes: anormal responders: patients with ovarian reserve and possibilities of pregnancy by ArT; bpoor responders: patients with reduction of ovary reserve and difficult 
therapeutic response; cno response: patients to send to IVF or FIVeT; dpatients with PcOs.
Abbreviations: ArT, assisted reproductive technology; IVF, in vitro fertilization; FIVeT, in vitro embryo transfer; nv, normal value; PcOs, polycystic ovary syndrome.
Table 2 Irccs Burlo Garofolo normal values vs others AA
Authors Manufacturers Normal values  
(ng/mL)
Patient age  
(years)
N PCOS values  
(ng/mL)
Patient age  
(years)
N
de Vet30 Ic 1.3 32 ± 4 41 – – –
Pigny12 Bc 2.91 27 45 6.59 28 59
Franchin31 Bc 1.39 34 75 – – –
eldar-Geva23 Ic 1.6 30.7 23 4.2 29.8 29
La Marca6 Bc 3.8 ± 1.2 21 12 – – –
Tsepelidis11 DsL 2.4 26.5 20 – – –
Wachs24 DsL 2.13 ± 0.4 26.5 11 7.22 ± 0.5 26.5 16
Das32 DsL 1.13 32 8 8.5 28 11
nardo14 DsL 2.4 ± 1.7 ,40 128 5.9 ± 2.3 ,40 37
Dorgan33 DsL 3.5 ± 4.08 36.5 20 – – –
Arabzadeh17 Ic 3.2 33 42 14.2 29 26
Falbo34 Bc 1.56 ± 1.02 28.17 10 3.92 ± 1.62 27.83 20
Parco35 Bc 1.22 36.4 86 10.0 31.05 5
Abbreviations: Bc, Beckman coulter; Ic, Immunotech coulter; DsL, Diagnostic system Laboratory.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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diverse absorbance concentrations (Pasquinelli and Porta, 
1994), according to instructions supplied in the analysis kit. 
FSH levels for all the patients was measured, as well as LH 
(only in six patients with very elevated AMH levels) using 
an automated colorimetric method (Modular P, Elecsys). All 
patients underwent a baseline pelvic ultrasound.
Results and discussion
In this study, we analyzed 236 serum samples from patients 
aged 26–46 years who had been referred to our institution for 
medically assisted fertility in September 2010 to June 2011. 
We identified 57 patients who were starting in vitro fertiliza-
tion or embryo transfer with AMH values within the normal 
range (3.64 ± 1.51 ng/mL), 77 with values below normal 
(1.38 ± 0.32 ng/mL), and 96 cases with undetectable values 
of AMH. Six patients had very high AMH levels (10.0 ± 
2.28 ng/mL) and, of these, five were found to have PCOS on 
pelvic ultrasound examination (P , 0.05; Table 1).
We also compared our values with those reported in the 
literature. The published studies have reported the average val-
ues for patients who were part of control groups or had PCOS. 
Comparing the values that we obtained with those of other 
laboratories, it can be seen that the average values of controls 
are lower than those in patients with PCOS, confirming the 
validity of the test as an indicator of this syndrome (Table 2).
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Figure 1 Graphic correlation: AMH vs FSH (IRCCS Burlo Garofolo).
Abbreviations: AMh, anti-Müllerian hormone; Fsh, follicle-stimulating hormone.
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Figure 2 Graphic correlation: AMH vs age (IRCCS Burlo Garofolo).
Abbreviation: AMh, anti-Müllerian hormone.
Moreover, numerous studies have identified an 
inverse correlation between AMH levels, FSH levels, and 
patient age. Therefore, we attempted to confirm these 
correlations in our group of patients and FSH levels were 
also measured in serum samples, showing an average 
value of 8.53 mIU/mL (follicular phase normal range 
3.5–12.5 mIU/mL) (Figures 1–3).
The cost-effective dosage of AMH is similar to that of 
other hormones, such as FSH and LH.
Conclusion
Many studies published in recent years have demonstrated 
that the concentration of AMH is 3–4 times higher in patients 
affected by PCOS than in patients without the disease. There are 
two hypotheses to explain this finding. One is that the follicles 
are transformed into cysts when they are at the preantral or 
antral stage, and remain at this stage and continue to secrete the 
hormone, and the other is that granulosa cells secrete a greater 
concentration of AMH, detectable at the follicular level.
In our case histories, the changes in reproductive state and 
AMH levels are confirmed by levels of FSH and LH. This 
inverse correlation has been found in many studies in the 
literature, and is confirmed by the present study.21–25
Our data emphasize that AMH can be used to identify 
PCOS and is a reliable marker of infertility associated with 
patient age and other hormonal tests, such as FSH, because it 
is influenced by the menstrual cycle, or identification by means 
of invasive tests such as transvaginal or laparoscopic ultra-
sound for follicular count and residual ovarian capacity.
In conclusion, AMH is confirmed as a useful test to study 
folliculogenesis and ovarian potential in various   situations of 
infertility and for identification of PCOS, to avoid the possibil-
ity of subjecting patients at risk to ineffective assisted repro-
ductive technology, and using in vitro fertilization or in vitro 
embryo transfer only after careful clinical assessment.26–35
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Figure 3 Graphic correlation: AMH and age (literature data).
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